Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Among DPP-4 inhibitors, gemigliptin is a relatively recently developed drug, and many
clinical studies have shown results that are equivalent to or superior to existing DPP-4
inhibitors such as sitagliptin. However, studies on the safety of gemigliptin in
cardiovascular disease have not been conducted, and studies on its effect on cardiac function
are lacking. Considering the increase in hospitalizations due to heart failure found in some
DPP-4 inhibitor studies, investigation of directly effect of gemigliptin on heart function
would be clinically important.